Early alteration in bone metabolism in epileptic children receiving carbamazepine monotherapy owing to the induction of hepatic drug-metabolizing enzymes

Journal of Child Neurology

Volumn 20, Issue 6, 2005, Pages 513-516

  Voudris, Konstantinos A ^a   Attilakos, Achilleas ^b   Katsarou, Eustathia ^a   Garoufi, Anastasia ^b   Dimou, Stamatia ^a   Skardoutsou, Angeliki ^b   Mastroyianni, Sotiria ^a  

^a P AND A KYRIAKOU CHILDREN S HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; ASPARTATE AMINOTRANSFERASE; CALCIUM; CARBAMAZEPINE; DRUG METABOLIZING ENZYME; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; LIVER ENZYME; MAGNESIUM; PHOSPHORUS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BENIGN CHILDHOOD EPILEPSY; BONE DISEASE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METABOLISM; MAGNESIUM BLOOD LEVEL; MALE; MONOTHERAPY; PHOSPHATE BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUN EXPOSURE;

EID: 22544482035     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/088307380502000608     Document Type: Article

References (27)

1. Kazamatsuri H: Elevated serum alkaline phosphatase levels in epilepsy during diphenylhydantoin therapy. N Engl J Med 1970;283:1411-1412.
2. O'Hare JA, Duggan B, O'Driscoll D, Callaghan N. Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurol Scand 1980;62:282-286.
3. Tjellesen L, Nilas L, Christiansen C: Does carbamazepine cause disturbances in calcium metabolism in epileptic patients? Acta Neurol Scand 1983;68:13-19.
4. Ala-Houhala M, Korpela R, Koivikko M, et al: Long-term anticonvulsant therapy and vitamin D metabolism in ambulatory pubertal children. Neuropediatrics 1986;17:212-216.
5. Collins N, Maher J, Cole M, et al: A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. QJM 1991;78:113-122.
6. Filardi S, Guerreiro CAM, Magna LA, Neto JFM: Bone mineral density, vitamin D, and anticonvulsant therapy. Arq Neuropsiquiatr 2000;58:616-620.
7. Valimaki MJ, Tiihonen M, Laitinen K, et al: Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994;9:631-637.
8. Akin R, Okutan V, Sarici U, et al: Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol 1998;19:129-131.
9. Kafali G, Erselcan T, Tanzer F: Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr 1999;38:93-98.
10. Allay EE, Serdanoglou A, Tumer L, et al: Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000;13:933-939.
11. Verrotti A, Greco R, Morgese G, Chiarelli F: Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000;47:385-388.
12. Voudris K, Moustaki M, Zeis PM, et al: Alkaline phosphatase and its isoenzyme activity for the evaluation of bone metabolism in children receiving anticonvulsant monotherapy. Seizure 2002;11:377-380.
13. Verrotti A, Greco R, Latini G, et al: Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002;43:1488-1492.
14. Heller HJ, Sakhaee K: Anticonvulsant-induced bone disease. A plea for monitoring and treatment. Arch Neurol 2001;58:1352-1353.
15. Sheth RD: Bone health in epilepsy. Epilepsia 2002;43:1453-1454.
16. Watts NB: Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999;45:1359-1368.
17. Meyer-Sabellek W, Sinha P, Kottgen E: Alkaline phosphatase: Laboratory and clinical implications. J Chrom 1988;429:419-444.
18. Looker AC, Bauer DC, Chesnut CH, et al: Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteoporos Int 2000;11:467-480.
19. Ross PD, Kress BC, Parson RE, et al: Serum bone alkaline phosphatase and calcaneous bone density predict fractures: A prospective study. Osteoporos Int 2000;11:76-82.
20. Christiansen C, Rodbro P, Lund M: Incidence of anticonvulsant osteomalacia and effect of vitamin D: Controlled therapeutic trial. BMJ 1973;4:695-701.
21. Richens A, Rowe DJ: Disturbance of calcium metabolism by anticonvulsant drugs. BMJ 1970;4:73-76.
22. Kruse K, Bartels H, Gunther H: Serum alkaline phosphatase isoenzymes in epileptic children receiving anticonvulsant drugs. Eur J Pediatr 1977;126:237-242.
23. Okesina AB, Donaldson D, Lascelles PT: Isoenzymes of alkaline phosphatase in epileptic patients receiving carbamazepine monotherapy. J Clin Pathol 1991;44:480-482.
24. Farhat G, Yamuot B, Mikati MA, et al: Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-1353.
25. Sheth RD, Wesolowski CA, Jacob JC, et al: Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-262.
26. Hahn TJ, Hendin BA, Scarp CR, Haddad JG Jr: Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol level in adults. N Engl J Med 1972;287:900-904.
27. Chung S, Ahn C: Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994;16:382-385.